Beckman Coulter Life Sciences Names Joe Fox President
Advertisement
Beckman Coulter Life Sciences announces the appointment of Joe Fox as President of the company effective immediately. Fox joins Beckman Coulter Life Sciences from SCIEX, also an Operating Company of Danaher Corporation, where he held positions of increasing responsibility over the past 13 years, most recently serving as President.

Joe Fox
Beckman Coulter Life Sciences
“Joe is a proven leader with a strong track record of successfully growing businesses and building diverse, inclusive and engaged teams in the life science and clinical industries,” said Greg Milosevich, Vice President and Group Executive of the Danaher Life Sciences Innovations Group. “He uniquely understands our strategy, culture of our Danaher Business System (DBS), and has a strong commitment to customer excellence. Joe will help Beckman Coulter Life Sciences continue to deliver meaningful innovation while developing and attracting top talent.”
“This is a pivotal time in the life sciences industry with many life-saving breakthroughs on the edge of discovery, all while many laboratories are navigating unique challenges,” said Fox. “At Beckman Coulter Life Sciences, our passion is solving customer problems. We will lead the way with customizable, sustainable solutions that accelerate and simplify complex workflows in service to our customers. Together, we’ll tackle global health challenges, revolutionize healthcare, and elevate patient care.”
Fox will lead a global team of more than 3,300 associates, driving product and service innovation to deliver workflow solutions in areas including Centrifugation, Flow Cytometry, Genomics, Particle Analysis, and Liquid Handling. He will also champion the Beckman Coulter Life Sciences commitment to sustainability which includes further integrating sustainability into operations, products, and packaging.
Prior to joining SCIEX, Fox held both technical and commercial roles with Bruker and Shimadzu. He holds a Bachelor of Science Degree in Biochemistry from the University of Delaware and a Ph.D. in Chemistry from Johns Hopkins University.
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Jung Foundation honours cutting-edge research: 4 prizes for medical breakthroughs - Their research has the potential to decisively transform the medicine of tomorrow, or has already done so

Leadership change at Köttermann B.V. in the Netherlands

1.2 million US dollar award honors pioneering work in cryo-electron tomography - Wolfgang Baumeister receives prestigious Shaw Prize

Leon-nanodrugs appoints Dr. Wolfgang Hofmann as Chief Executive Officer

Refeyn Announces Leadership Transition - Jonathan Flint Steps Down as Chairman, Jean-Paul Mangeolle Appointed as Successor

Joachim Kreuzburg, Former CEO of Sartorius, Joins Cube Biotech’s Board of Directors

New high-tech startup developing smart contact lenses for glaucoma diagnosis and management

Insilico Medicine brings AI-powered “ChatPandaGPT” to its target discovery platform - A revolution in drug discovery thanks to a new chat assistant?

Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”

Waters Corporation and Princeton University Announce Multi-Year Research Collaboration - Agreement to take on real-world challenges in biologics and materials research

New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments
